Prospective data observed with the gemcitabine intravesical system may be superior to prior reports of other therapies in BCG-unresponsive NMIBC.
FDA Approval Alert: The Need-to-Know
Advertisement
According to Jorge Nieva, MD, taletrectinib may be a primary frontline therapy option for those with ROS1-positive non–small cell lung cancer.
Advertisement
Advertisement
Trending on CancerNetwork
1
Data Readouts to Watch at the 2026 ASCO Annual Meeting
2
Outlining Exercise as a “Biologically Interventional Therapy” for Cancer
3
FDA OKs Updated Guardant360 Liquid CDx with Expanded Molecular Profiling
4
FDA Approves Dato-DXd for Metastatic Triple-Negative Breast Cancer
5